may have gone undetected. We hypothesized that hemorrhagic transformation of postprocedural bland ischemic lesions is the main cause of delayed ICH following PED treatment and that PED-treated patients might have an increased risk of hemorrhagic transformation compared with those treated with standard stent-assisted coiling methods. This hypothesis is based on several reports showing that PED treatment is correlated with a higher rate of ipsilateral ischemic lesions on diffusion-weighted MRI (DWI) compared with conventional stent-assisted coiling methods. 13, 14, 16 Some of these lesions may progress to massive hemorrhages with neurological deterioration. T2*-weighted MRI (T2*WI) has proven more sensitive for detecting cerebral microbleeds as hypointense lesions than have CT and other MRI methods. 5, 12, 21, 27 Cerebral microbleeds are considered a potential risk factor for more extensive cerebral bleeding. 2, 10 The occurrence of hemorrhagic transformation of ischemic lesions following PED treatment may be detectable by T2*WI in previously infarcted foci. It has not been clear whether new microbleeds occur in microinfarcts appearing postprocedure or in other locations. Here, we analyzed pre-and posttreatment images and the rate of delayed microbleeds demonstrated on T2*WI in patients treated with PED and conventional stent devices.
Methods

Patient Population
We retrospectively reviewed the demographic, clinical, and radiological characteristics of 28 consecutive patients who underwent PED placement (PED group) at our hospital from November 2015 to March 2017. According to the Japanese government approval of the PED, we included patients who had presented with an unruptured intracranial aneurysm of ≥ 10 mm in maximum diameter with a neck of ≥ 4 mm occurring between the petrous and superior hypophyseal segments and proximal to the posterior communicating segment of the internal carotid artery. Patients with recanalized aneurysms who required re-treatment after a previous embolization were also included. In addition, the imaging data of 24 consecutive patients who underwent stent-mediated embolization (Enterprise, Codman and Shurtleff; or Neuroform, Stryker) (EN group) at our institution between December 2010 and October 2015 were included for comparison. The inclusion criteria for the target aneurysms of the comparison group were the same as those for the PED group. We collected data on patient age; sex; comorbidities, including hypertension, diabetes mellitus, hyperlipidemia, and smoking status; maximum aneurysm diameter and neck diameter; type of stent; instances of coil embolization; procedure time (incision to stent placement, balloon angioplasty, or coil embolization, whichever was later); and modified Rankin Scale (mRS) 33 score (0 = asymptomatic; 6 = death) at 6 months postprocedure. This study was approved by the hospital's institutional review board.
Patient Assessment
All patients underwent catheter-based cerebral angiography conducted using the Siemens Artis zee system (Siemens Healthineers) (through February 2014) or the Siemens Artis Q system (beginning in March 2014). Aneurysm measurements were obtained from pretreatment digital subtraction angiography and 3D rotational angiography studies. The aneurysm neck was defined as the largest diameter along any plane at the junction with the parent artery. All patients were pretreated with aspirin (100 mg per day orally for 7 days) and clopidogrel (75 mg per day orally for 7 days). Aspirin reaction units (ARUs) and P2Y12 reaction units (PRUs) were calculated using the rapid platelet function assay VerifyNow (Accumetrics, Inc.) to determine aspirin and clopidogrel resistance. An abnormal antiplatelet response was defined as > 550 ARUs and/or > 240 PRUs. 8, 18, 25 The aspirin or clopidogrel dose was increased, or cilostazole (200 mg per day) was prescribed, when resistance was detected. Patients in both groups continued to receive aspirin and clopidogrel therapy for at least 6 months following treatment.
One endovascular neurosurgeon (A.H.) conducted all surgical procedures, which were performed under general anesthesia. After securing arterial access, patients were administered intravenous heparin to obtain a 250-second activated clotting time. In the PED group, balloon angioplasty was performed if PED expansion was inadequate. Adjunctive coils were used via a jailed microcatheter after PED placement in cases of high inflow into the intracranial aneurysm, which is thought to be a risk factor for postprocedural rupture. 20, 26 Appropriate wall apposition of stents was assessed using multiplanar reconstructed dynamic CT imaging.
MRI Review
All patients underwent MRI using the Siemens MAG-NETOM Avanto 1.5-T MRI system (Siemens Healthineers) (through March 2014) or the Siemens MAGNE-TOM Skyra 3-T MRI system (beginning in April 2014). MRI scans, including DWI and T2*WI pretreatment and 24-36 hours posttreatment, were routinely obtained in both groups. Patients were scheduled for a 6-month followup. Three patients whose follow-up MRI studies could not be obtained were excluded. The pre-and postembolization MRI and 6-month follow-up MRI studies for each patient were independently scored by 2 reviewers (R.N. and Y.K.) for the presence of procedure-related DWI and T2*WI lesions, and the absolute values of the number of DWI and T2*WI lesions on each MRI study were noted (Figs. 1 and 2). On each follow-up MRI study, only new T2*WI lesions that were not present on the preprocedural MRI study were scored.
Statistical Analysis
Analysis was conducted using commercial software (IBM SPSS, version 24.0, IBM Corp.). Demographic, clinical, and radiological parameters for the 2 groups were analyzed using the Student t-test, Mann-Whitney U-test, or chi-square test for continuous normally distributed, continuous nonnormally distributed, and dichotomous data, respectively. Statistical significance was defined as p < 0.05. 
Results
Patient Characteristics
Demographic, clinical, and radiological characteristics of patients are summarized in Table 1 . The PED group comprised 28 patients with 30 intracranial aneurysms. The EN group comprised 24 patients with 27 intracranial aneurysms. Age; sex; presence of hypertension, diabetes mellitus, or hyperlipidemia; smoking status; maximum aneurysm diameter; and aneurysm neck diameter were comparable between the groups. The mean procedure time was shorter in the PED group than in the EN group (82.2 minutes vs 143 minutes, p < 0.0001). There was no significant difference in mRS score at 6 months postprocedure between the groups.
MRI Findings 1 Day Postprocedure
The mean number of new ischemic lesions detected on DWI 1 day postprocedure was higher in the PED group than the EN group (5.2 vs 2.7, p = 0.0010). No microbleeds were observed on T2*WI on day 1 postprocedure in either the PED or EN group (Table 2) .
MRI Findings 6 Months Postprocedure
The prevalence of microbleeds detected on T2*WI at 6 months postprocedure was significantly higher in the PED group than in the EN group (36.7% vs 11.1%, p = 0.025; Table 2 ). All microbleeds were asymptomatic. The mean number of microbleeds per patient at 6 months postprocedure was also higher in the PED group than in the EN group (0.6 vs 0.15, p = 0.028). All microbleeds were observed distal to the stented artery. All microbleeds in the EN group were observed in the same infarcted area as that noted on DWI performed 1 day postprocedure, while 22.2% of microbleeds in the PED group were found distant from DWI bland lesions observed 1 day postprocedure; however, there was no significant difference between the groups.
Predictors of Microbleeds
We evaluated predictors of microbleeds by comparing patients with and without microbleeds at 6 months postprocedure (Table 3 ). The use of PEDs (78.6% vs 44.2%, p = 0.025), the overall rate of ischemic lesions observed on DWI 1 day postprocedure (100.0% vs 74.4%, p = 0.035), and the mean number of ischemic lesions per patient (5.9 vs 3.3, p = 0.0042) were higher in patients with, compared with those without, microbleeds.
Predictors of Microbleeds in the PED Group
We evaluated predictors of microbleeds in the PED group by comparing patients with and without microbleeds at 6 months postprocedure (Table 4 ). The rate of adjunctive coil embolization was significantly higher in patients with, compared with those without, microbleeds (27.3% vs 0.0%, p = 0.016). While the overall rate of ischemic lesions ob- Values represent the number of aneurysms (%) unless otherwise specified. Mean values are presented as the mean ± SD.
served on DWI 1 day postprocedure did not differ between patients with and without microbleeds, the mean number of ischemic lesions per patient was higher in patients with microbleeds (6.6 vs 4.3, p = 0.020).
Discussion
We found that the mean number of ischemic lesions observed on DWI 1 day postprocedure was higher in the PED group than in the EN group. The mean number of microbleeds observed on T2*WI 6 months postprocedure was also higher in the PED group than in the EN group. A total of 36.7% of PED-treated patients had new microbleeds according to T2*WI 6 months postprocedure, with at least 77.8% of these being hemorrhagic transformations of ischemic lesions observed on day 1 postprocedure.
Several studies have shown that embolic risk is significantly increased with FD use compared with conventional stent-assisted coiling. 13 16 This is consistent with our findings, where 27 of 30 (90.0%) patients treated with PED showed hyperintense lesions on postprocedural DWI. Several studies have suggested that delayed ipsilateral ICH may be a potential complication of FD treatment of intracranial aneurysms. 3, 4, 6, 7, 11, 15, 34 The pathophysiology of this condition is unknown. Brinjikji et al. 3 showed that ICH incidence increased 4-fold after treatment with multiple PEDs due to secondary hemorrhagic transformation of the resulting ischemic infarcts, which may arise from the exposure of platelets to a much greater surface area of metal. Our findings indicate that the number of new bland ischemic lesions detected on DWI 1 day postprocedure is predictive of subsequent microbleeds in patients treated with FDs. This in turn suggests that an intraprocedural or postprocedural infarction, which may have occurred as a result of thrombus formation on the stent with subsequent embolization, can cause delayed ICH. While most patients with hemorrhagic transformation of ischemic lesions show no obvious signs of clinical deterioration, hemorrhage expansion can exacerbate neurovascular damage and may result in symptomatic ICH. Considering that 36.7% of PEDtreated patients in the present study had new microbleeds detected on T2*WI 6 months postprocedure, it may be pertinent to control perioperative blood pressure to lower the risk of hemorrhagic transformation and subsequent expansion of ischemic lesions.
We also found that 22.2% of microbleeds in the PED group 6 months postprocedure occurred in areas distant from DWI lesions observed on day 1 postprocedure. Safain et al. 28 demonstrated an association between PED and continued new and independent ipsilateral FLAIR signal abnormalities on MRI ≤ 1 year after PED treatment. These lesions were not associated with any previous abnormalities identified on DWI or FLAIR, suggesting that they may have been delayed ischemic events and were most likely embolic from the stent/aneurysm complex. In the present study, 2 asymptomatic delayed ICHs located distal to the stented artery were detected in the PED group on CT performed 6 and 7 days postprocedure. One was detected in the same infarcted area as that observed on DWI 1 day postprocedure (Fig. 3) , and the other was detected in an area different from that of the bland infarcted area observed on DWI 1 day postprocedure (Fig. 4) . 23 We propose that in the latter case, hemorrhagic transformation of an embolic infarction that occurred > 2 days postprocedure may have been the cause of delayed ICH.
Dual antiplatelet therapy is a common cause of hemorrhagic complications. The annual risk of major ICH with dual antiplatelet therapy for secondary stroke prevention is 1.1%-1.8%. 9, 29 The hemorrhagic risk of stent-assisted coiling of unruptured intracranial aneurysms with dual antiplatelet therapy is 2.2%-2.6%. 19, 30 Sim et al. 31 showed that the incidence of remote ICH following endovascular treatment of unruptured intracranial aneurysms was 0.46%, which occurred more frequently in patients who received stent-assisted coiling with dual antiplatelet therapy than in those receiving coiling alone with antiplatelet monotherapy. They proposed that changing non-flow-diverting stents to FDs increased the incidence of ICH, suggesting that FD use with dual antiplatelet therapy might play a major role in causing remote ICH.
Another proposed hypothesis for the occurrence of delayed ipsilateral ICH is that exchanging a relatively compliant wall for a rigid stent alters pressure transmission across the segment, 3, 6 reducing the Windkessel effect, 6 which describes a higher distal pulse pressure due to lower blood vessel elasticity. These changes may cause remote ICHs that arise within the same region as the segment in which the stent is deployed. The Windkessel effect may also be behind the finding that PED-treated patients have an increased risk of remote ICH compared with those receiving standard stent-assisted coiling.
We found that adjunctive coils in the PED group tended to confer a risk of subsequent microbleeds. Adjunctive coils in PED-treated patients have been linked to the formation of new hyperintense lesions on postprocedural DWI, which can in turn lead to hemorrhagic transformation because adjunctive coils require a jailed microcatheter, and the number of microcatheters is strongly associated with DWI abnormalities. 32 Further studies are needed to determine whether adjunctive coil embolization with PED deployment is correlated with ischemic lesions and hemorrhagic transformation.
This study has several limitations. First, we had a relatively small sample size, which could not provide sufficient power for comprehensive statistical analysis. We therefore did not conduct multivariate logistic regression analysis but were instead restricted to conducting univariate analyses for predictors of microbleeds in the PED group. Further studies are needed to increase the database to allow multivariate analysis in order to better determine independent risk factors for new microbleeds. Second, some of the is- chemic lesions on DWI 1 day postprocedure might be associated with the catheter delivery procedure. Third, not all patients underwent MRI between day 1 and 6 months postprocedure. We observed delayed ICH in 2 patients in whom scans were performed at 6 and 7 days postprocedure. It is possible that we might have detected more delayed ICH if we had had all patients undergo MRI at more than one point early in the postoperative period.
Conclusions
New microbleeds detected on T2*WI 6 months postprocedure were common after PED treatment. The majority of these were hemorrhagic transformations of ischemic lesions that developed 1 day postprocedure. Asymptomatic microbleeds have the potential to become symptomatic ICH. Intraprocedural and postprocedural infarct reduction methods are needed to reduce the risk of hemorrhagic complications following PED placement.
